GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pentixapharm Holding AG (XTER:PTP) » Definitions » EV-to-FCF

Pentixapharm Holding AG (XTER:PTP) EV-to-FCF : -5.35 (As of Apr. 07, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Pentixapharm Holding AG EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Pentixapharm Holding AG's Enterprise Value is €58.09 Mil. Pentixapharm Holding AG's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was €-10.86 Mil. Therefore, Pentixapharm Holding AG's EV-to-FCF for today is -5.35.

The historical rank and industry rank for Pentixapharm Holding AG's EV-to-FCF or its related term are showing as below:

XTER:PTP' s EV-to-FCF Range Over the Past 10 Years
Min: -37.79   Med: -23.82   Max: -5.35
Current: -5.35

During the past 3 years, the highest EV-to-FCF of Pentixapharm Holding AG was -5.35. The lowest was -37.79. And the median was -23.82.

XTER:PTP's EV-to-FCF is ranked worse than
100% of 460 companies
in the Biotechnology industry
Industry Median: 2.335 vs XTER:PTP: -5.35

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-04-07), Pentixapharm Holding AG's stock price is €2.795. Pentixapharm Holding AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.298. Therefore, Pentixapharm Holding AG's PE Ratio (TTM) for today is At Loss.


Pentixapharm Holding AG EV-to-FCF Historical Data

The historical data trend for Pentixapharm Holding AG's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pentixapharm Holding AG EV-to-FCF Chart

Pentixapharm Holding AG Annual Data
Trend Dec21 Dec22 Dec23
EV-to-FCF
- - -

Pentixapharm Holding AG Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24
EV-to-FCF - - - - -

Competitive Comparison of Pentixapharm Holding AG's EV-to-FCF

For the Biotechnology subindustry, Pentixapharm Holding AG's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pentixapharm Holding AG's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pentixapharm Holding AG's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Pentixapharm Holding AG's EV-to-FCF falls into.


;
;

Pentixapharm Holding AG EV-to-FCF Calculation

Pentixapharm Holding AG's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=58.094/-10.856
=-5.35

Pentixapharm Holding AG's current Enterprise Value is €58.09 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pentixapharm Holding AG's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was €-10.86 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pentixapharm Holding AG  (XTER:PTP) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Pentixapharm Holding AG's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.795/-0.298
=At Loss

Pentixapharm Holding AG's share price for today is €2.795.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pentixapharm Holding AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.298.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Pentixapharm Holding AG EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Pentixapharm Holding AG's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Pentixapharm Holding AG Business Description

Traded in Other Exchanges
Address
Robert-Rossle-Street 10, Berlin, DEU
Pentixapharm Holding AG is a clinical-stage biopharmaceutical company active in the field of research and development of radiopharmaceuticals for diagnostic and therapeutic applications. Radiopharmaceuticals are medical substances containing radioactive elements used in nuclear medicine to diagnose or treat diseases. Its clinical pipeline encompasses PentixaTher, a Yttrium-90 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68-based companion diagnostic.

Pentixapharm Holding AG Headlines

No Headlines